TENX
Tenax Therapeutics Inc.
$15.03
+$0.44(+3.02%)
67
Overall
60
Value
75
Tech
--
Quality
Market Cap
$29.25M
Volume
317.46K
52W Range
$4.63 - $18.38
Target Price
$28.67
Order:
Income Statement
| Metric | Trend | Chart | 2015 Apr | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $49.3K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Total Revenue | $49.3K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-14.9M | $-52.7M | $-9.2M | $-6.9M | $8.6M | $9.9M | $32.7M | $11.1M | $8.2M | $19.5M | ||
| Research & Development | $6.7M | $13.1M | $3.5M | $1.2M | $3.5M | $4.6M | $25.1M | $5.4M | $3.2M | $12.7M | ||
| Research Expense | $6.7M | $13.1M | $3.5M | $1.2M | $3.5M | $4.6M | $25.1M | $5.4M | $3.2M | $12.7M | ||
| Selling, General & Administrative | $7.2M | $6.2M | $5.7M | $5.7M | $5.1M | $5.3M | $7.6M | $5.7M | $5.0M | $6.8M | ||
| Selling & Marketing Expenses | $7.2M | $6.2M | $5.7M | $5.7M | $5.1M | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $-111.2K | $-91.2K | $-112.4K | $-115.2K | -- | $5.3M | $7.6M | $5.7M | $5.0M | $6.8M | ||
| Salaries & Wages | -- | -- | -- | -- | -- | -- | -- | -- | $116.0K | $998.0K | ||
| Depreciation & Amortization | $-77.8K | $-19.0K | $-13.6K | $-9.0K | $-5.0K | $4.1K | $4.1K | $5.1K | $7.6K | -- | ||
| Depreciation & Amortization | $-77.8K | $-19.0K | $-13.6K | $-9.0K | $-5.0K | $4.1K | $4.1K | $5.1K | $7.6K | -- | ||
| Amortization | $-91.7K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | $-14.9M | $-52.7M | -- | -- | -- | $18.2K | $254.8K | -- | $8.2M | $19.5M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-13.8M | $-19.4M | $-9.2M | $-6.9M | $-8.6M | $9.9M | $-32.7M | $-11.1M | $-8.2M | $-19.5M | ||
| EBITDA | $-13.2M | $-51.3M | $-8.6M | $-6.7M | $-8.3M | $-9.7M | $-32.4M | $-10.9M | $-7.7M | $-17.7M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $49.1K | -- | -- | -- | -- | $-1.6K | $949 | $4.4K | $24.0K | $23.0K | ||
| Net Non-Operating Interest Income/Expense | $-49.1K | -- | -- | -- | -- | $1.6K | $-949 | $-4.4K | $-24.0K | $-23.0K | ||
| Gain on Sale of Securities | $-26.7K | $-110.7K | $-2.5K | $-16.7K | $58 | $528 | $-70 | -- | -- | -- | ||
| Other Income/Expense | $277.6K | $32.6M | $-363.7K | $-63.1K | $-161.0K | $-528 | $-254.8K | $9.2K | $-63.0K | $-1.0K | ||
| Other Special Charges | $784.0K | $764.7K | $366.2K | $79.8K | $160.9K | $18.2K | $254.8K | $-9.2K | $63.0K | $1.0K | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | $106.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Impairment of Capital Assets | $-106.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-14.1M | $-52.0M | $-8.8M | $-6.8M | $-8.4M | $-9.8M | $-32.5M | $-11.0M | $-7.7M | $-17.7M | ||
| Pre-Tax Income | $-14.1M | $-52.0M | $-8.8M | $-6.8M | $-8.4M | $-9.9M | $-32.5M | $-11.0M | $-8.2M | $-19.5M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | $-8.0M | -- | -- | -- | $-194.6K | $-73 | $218.2K | $-33.0K | $-94.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-14.1M | $-44.0M | $-8.8M | $-6.8M | $-8.4M | $-9.9M | $-32.5M | $-11.0M | $-7.7M | $-17.6M | ||
| Net Income (Continuing Operations) | $-14.1M | $-44.0M | $-8.8M | $-6.8M | $-8.4M | $-9.9M | $-32.5M | $-11.0M | $-7.7M | $-17.6M | ||
| Net Income (Discontinued Operations) | $-14.1M | $-44.0M | $-8.8M | $-6.8M | $-8.4M | $-9.9M | $-32.5M | $-11.0M | $-7.7M | $-17.6M | ||
| Net Income (Common Stockholders) | $-14.1M | $-44.0M | $-8.8M | $-14.2M | $-8.4M | $-9.9M | $-32.5M | $-11.0M | $-7.7M | $-17.6M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-32.5M | -- | -- | $-19.6M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-14.9M | $-52.7M | $-9.2M | $-6.9M | $8.6M | $9.9M | $32.7M | $11.1M | $8.2M | $19.5M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $877 | $1.4M | $70.5K | $78.2K | $309.8K | $4.6K | $12.9K | -- | $248.4K | $15.3M | ||
| Average Shares Outstanding (Diluted) | $877 | $1.4M | $70.5K | $37.8K | $309.8K | $4.6K | $12.9K | -- | $248.4K | $15.3M | ||
| Shares Outstanding | $878 | $70.3K | $3.6K | $307.7K | $4.8K | $9.4K | $15.8K | $280.0K | $2.0M | $4.0M | ||
| Basic EPS | -- | -- | -- | -- | -- | $-2.1K | $-2.5K | -- | $-31.04 | $-1.15 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-2.1K | $-2.5K | -- | -- | $-1.15 | ||
| Diluted EPS | $-16.0K | $-31.2 | $-125.4 | $-180.8 | $-27 | $-2.1K | $-2.5K | -- | $-31.04 | $-1.15 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $-27 | -- | -- | -- | -- | $-1.15 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | -- | -- | $7.3M | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $-111.2K | $-91.2K | $-112.4K | $-115.2K | -- | $5.3M | $7.6M | $5.7M | $5.0M | $6.8M | ||
| Other Impairment Of Capital Assets | $1.0M | $33.3M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Otherunder Preferred Stock Dividend | -- | -- | -- | $7.3M | -- | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | -- | -- | -- | $7.3M | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $-111.2K | $-91.2K | $-112.4K | $-115.2K | -- | -- | -- | -- | $-800 | $-1.0K | ||
| Selling Expense | $7.2M | $6.2M | $5.7M | $5.7M | $5.1M | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TENX | $15.03 | +3.0% | 317.46K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |